Cargando…
Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression
Breast cancer is one of the most commonly diagnosed malignancies. Although endocrine therapy improves the survival of patients with hormone receptor (HR)-positive breast cancer, the post-endocrine therapy strategy for metastatic breast cancer remains challenging. Herein, we report two patients who b...
Autores principales: | Wu, Dingyong, Tang, Shu, Ye, Rong, Li, Dongmei, Gu, Dejian, Chen, Rongrong, Zhang, Huan, Sun, Jianguo, Chen, Zhengtang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939121/ https://www.ncbi.nlm.nih.gov/pubmed/33692787 http://dx.doi.org/10.3389/fimmu.2021.610149 |
Ejemplares similares
-
Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma
por: Xu, Zhenying, et al.
Publicado: (2022) -
Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report
por: Chen, Cui, et al.
Publicado: (2022) -
Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023) -
Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma
por: Kao, Chien-Hsiang, et al.
Publicado: (2022) -
Alteration of Endocrine Hormones and Antibody Responses in Different Spectrum of Tuberculosis Disease
por: Tsegaye, Yosef, et al.
Publicado: (2022)